Characterization and evaluation of the directly observed treatment for tuberculosis in Santiago de Compostela (1996-2006)

Risk Management and Healthcare Policy

Volumn 3, Issue , 2010, Pages 21-26

  Mejuto, Beatriz ^a   Tuñez, Victoria ^b   del Molino, María Luisa Pérez ^b   García, Rosario ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

DOTS; Drugs; Recurrence; Selection criteria; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; AGED; ALCOHOLISM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIMARY TUBERCULOSIS; RECURRENT INFECTION; RETREATMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; SHORT COURSE THERAPY; SPAIN; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 78649796999     PISSN: None     EISSN: 11791594     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Global tuberculosis control: surveillance, planning, financing. WHO/ HTM/TB/2008.393. Geneva, Switzerland: World Health Organization, 2008.
2. Crofton J, Chaulet P, Maher D. Guidelines for the management of drugresistant tuberculosis.WHO/TB/96.210 (Rev.1) Geneva, Switzerland: World Health Organization, 1997.
3. Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIVinfected patients: a comprehensive review. Clini Microbiol Infect. 2004;1:388-398.
4. Ministerio de Sanidad y Consumo. Plan para la prevención y control de la tuberculosis en España. Documento aprobado por la Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud el 15 de Noviembre de 2007 y por el Consejo Interterritorial del Sistema Nacional de Salud el 18 de Junio de 2008. Madrid: 2008.
5. Programa Galego de Prevención e Control da Tuberculose. Documentos Técnicos en Saúde Pública: Serie B. NTT35. Ed. Xunta de Galicia. Consellería de Sanidade e Servicios Sociais. Dirección Xeral de Saúde Pública. Santiago 2003.
6. Cruz E, Fernández-Nogueira E. Epidemiology of tuberculosis in Galicia, Spain, 1996-2005. Int J Tuberc Lung Dis. 2007;11:1073-1079.
7. CDC. A strategic plan for the elimination of tuberculosis in the United States. MMWR 1989;38:1-25.
8. World Health Organization. WHO tuberculosis programme: Framework for effective tuberculosis control. WHO/TB/94.179. 1994. Available from: http://whqlibdoc.who.int/hq/1994/WHO-TB-94.179.pdf. Accessed on Mar 10, 2010.
9. World Health Organization. What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. WHO/CDC/ CPC/TB/99.270. Geneva, Switzerland: World Health Organization, 1999.
10. Direccion Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia. Programa galego de prevención e control da tuberculose. Documentos Técnicos en Saúde Pública. Serie A. NDD13. Santiago de Compostela, Spain: Dirección Xeral de Saúde Pública,1995.
11. Treatment of tuberculosis for national programmes. 3rd ed. WHO/ CDC/TB/2003.313. Geneva, Switzerland: World Health Organization, 2003.
12. Pérez del Molino ML, Túnez V, Cruz-Ferro E, et al. Study of Mycobacterium tuberculosis drug resistance in the region of Galicia, Spain. Int J Tuberc Lung Dis. 2005;9:1230-1235.
13. Bayer DW. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345:1545-1548.
14. Murray CJL, Styblo K, Roullion A. Tuberculosis in developing countries: burden intervention and cost. Bull Int Union Tuberc Lung Dis. 1990;65:6-24.
15. Altet N. Retraso diagnóstico en tuberculosis. Enf Emerg. 2006; 8:163-168.
16. Surveillance of tuberculosis in Europa-Euro TB. Report tuberculosis cases notified in 2006. Institut de veille sanitaire, Saint-Maurice, France. March 2008. Available from: http://www.erurtb.org. Accessed Mar 10, 2010.
17. Caminero Luna JA. La erradicación de la tuberculosis: ¿mito o realidad? Enf Emerg. 2006;8:271-281.
18. Crofton J, Chaulet P, Maher D. Directrices para el tratamiento de la tuberculosis fármacorresistente. WHO/TB/96.210 (Rev.1). Ginebra, Switzerland: Organization Mundial de la Salud; 1997.
19. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368:2142-2154.
20. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization, 2008.
21. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des. 2006;12:4047-4070.
22. De Souza MV, Vasconcelos TR, de Almeida MV, Cardoso SH. Fluoroquinolones: an important class of antibiotics against tuberculosis. Curr Med Chem. 2006;13:455-463.
23. Conde MB, Efron A, Loredo C, et al. Moxifloxacin in the initial therapy of tuberculosis: a randomized, phase 2 trial. Lancet. 2009;373:1183-1189.
24. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev. 2001;(4):CD000970.
25. Alvarez TA, Rodrigues MP, Viegas CA. Prevalence of drug-resistant Mycobacterium tuberculosis in patients under intermittent or daily treatment. J Bras Pneumol. 2009;35:555-560.
26. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008;336:484-487.
27. Juan G, Lloret T, Perez C, et al. Directly observed treatment for tuberculosis in pharmacies compared with self-administered in Spain. Int J Tuberc Dis. 2006;10:215-221.
28. Altet MN, Alcalde J, Canela J, et al. Estudio del retraso diagnóstico de la tuberculosis pulmonar sintomática. Arch Bronconeumol. 2003;39:146-152.